

## Product datasheet for **TL314547V**

### Axin 2 (AXIN2) Human shRNA Lentiviral Particle (Locus ID 8313)

#### Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Axin 2 (AXIN2) Human shRNA Lentiviral Particle (Locus ID 8313)
Locus ID:	8313
Synonyms:	AXIL; ODCRCS
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	AXIN2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, $>10^7$ TU/ml.
RefSeq:	<a href="#">BC006295</a> , <a href="#">NM_004655</a> , <a href="#">NM_004655.1</a> , <a href="#">NM_004655.2</a> , <a href="#">NM_004655.3</a> , <a href="#">BC006295.2</a> , <a href="#">BC101533</a> , <a href="#">BC101533.1</a> , <a href="#">BC143244</a> , <a href="#">NM_001363813</a>
UniProt ID:	<a href="#">Q9Y2T1</a>
Summary:	The Axin-related protein, Axin2, presumably plays an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway, like its rodent homologs, mouse conductin/rat axil. In mouse, conductin organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and conductin, which leads to the degradation of beta-catenin. Apparently, the deregulation of beta-catenin is an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair. [provided by RefSeq, Jul 2008]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .




[View online »](#)


**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.


For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

**Product images:**


GFP signal was observed under microscope at 48 hours after transduction of TL314547A virus into HEK293 cells. TL314547A virus was prepared using lenti-shRNA TL314547A and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of TL314547B virus into HEK293 cells. TL314547B virus was prepared using lenti-shRNA TL314547B and [TR30037] packaging kit.



GFP signal was observed under microscope at 48 hours after transduction of [TL314547C] virus into HEK293 cells. [TL314547C] virus was prepared using lenti-shRNA [TL314547C] and [TR30037] packaging kit.